Loading...
Loading...
ANTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 16.6M |
| Operating I/L | -16.6M |
| Other Income/Expense | 0.8M |
| Interest Income | 0.0M |
| Pretax | -15.8M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -15.8M |
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing treatments for rare, chronic, and serious infectious diseases. Their primary focus is on the development of epetraborole, a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. The company's revenue model is centered around the research, development, and commercialization of innovative pharmaceutical solutions to address unmet medical needs in the infectious disease space.
